Intestinal Research

IBD
Use of thiopurines in inflammatory bowel disease: an update: Arshdeep Singh, Ramit Mahajan, Saurabh Kedia, Amit Kumar Dutta, Abhinav Anand, Charles N. Bernstein, Devendra Desai, C. Ganesh Pai, Govind Makharia, Harsh Vardhan Tevethia, Joyce WY Mak, Kirandeep Kaur, Kiran Peddi, Mukesh Kumar Ranjan, Perttu Arkkila, Rakesh Kochhar, Rupa Banerjee, Saroj Kant Sinha, Siew Chien Ng, Stephen Hanauer, Suhang Verma, Usha Dutta, Vandana Midha, Varun Mehta, Vineet Ahuja, Ajit Sood; Intest Res. 2022;20(1):11-30. Published online April 15, 2021; DOI: https://doi.org/10.5217/ir.2020.00155
Cited By 25; Full text PubReader ePub Crossref - TDM PDF

Intestinal tuberculosis or Crohn’s disease: a review of the diagnostic models designed to differentiate between these two gastrointestinal diseases: Julajak Limsrivilai, Nonthalee Pausawasdi; Intest Res. 2021;19(1):21-32. Published online April 22, 2020; DOI: https://doi.org/10.5217/ir.2019.09142
Cited By 24; Full text PubReader ePub Crossref - TDM PDF

Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?: Sang Hyoung Park; Intest Res. 2022;20(2):159-164. Published online April 29, 2022; DOI: https://doi.org/10.5217/ir.2021.00115
Cited By 22; Full text PubReader ePub Crossref - TDM PDF

Inflammatory Bowel Diseases
Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis: Shin Ju Oh, Ga Young Shin, Hosim Soh, Jae Gon Lee, Jong Pil Im, Chang Soo Eun, Kang-Moon Lee, Dong Il Park, Dong Soo Han, Hyo Jong Kim, Chang Kyun Lee; Intest Res. 2021;19(3):323-331. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00039
Cited By 20; Full text PubReader ePub Crossref - TDM PDF

IBD
Management of Clostridioides difficile infection in patients with inflammatory bowel disease: Sahil Khanna; Intest Res. 2021;19(3):265-274. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00045
Cited By 19; Full text PubReader ePub Crossref - TDM PDF

Miscellaneous
Patients with celiac disease are at high risk of developing metabolic syndrome and fatty liver: Ashish Agarwal, Alka Singh, Wajiha Mehtab, Vipin Gupta, Ashish Chauhan, Mahendra Singh Rajput, Namrata Singh, Vineet Ahuja, Govind K. Makharia; Intest Res. 2021;19(1):106-114. Published online April 22, 2020; DOI: https://doi.org/10.5217/ir.2019.00136
Cited By 19; Full text PubReader ePub Crossref - TDM PDF

IBD
Natural history of inflammatory bowel disease: a comparison between the East and the West: Eun Mi Song, Suk-Kyun Yang; Intest Res. 2022;20(4):418-430. Published online December 2, 2021; DOI: https://doi.org/10.5217/ir.2021.00104
Cited By 18; Full text PubReader ePub Crossref - TDM PDF

Inflammatory Bowel Diseases
Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry: Ajit Sood, Kirandeep Kaur, Ramit Mahajan, Vandana Midha, Arshdeep Singh, Sarit Sharma, Amarender Singh Puri, Bhabhadev Goswami, Devendra Desai, C. Ganesh Pai, Kiran Peddi, Mathew Philip, Rakesh Kochhar, Sandeep Nijhawan, Shobna Bhatia, N. Sridhara Rao; Intest Res. 2021;19(2):206-216. Published online July 13, 2020; DOI: https://doi.org/10.5217/ir.2019.09169
Cited By 17; Full text PubReader ePub Crossref - TDM PDF Graphic abstract

The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis: Yujin Jeong, Seong Ran Jeon, Hyun Gun Kim, Jung Rock Moon, Tae Hee Lee, Jae Young Jang, Jun-Hyung Cho, Jun Seok Park, Heesu Park, Ki-hun Lee, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Suyeon Park; Intest Res. 2021;19(1):62-70. Published online May 8, 2020; DOI: https://doi.org/10.5217/ir.2019.09156
Cited By 17; Full text PubReader ePub Crossref - TDM PDF

IBD
Management of inflammatory bowel disease in the COVID-19 era: Kyeong Ok Kim, Byung Ik Jang; Intest Res. 2022;20(1):3-10. Published online February 3, 2021; DOI: https://doi.org/10.5217/ir.2020.00156
Cited By 16; Full text PubReader ePub Crossref - TDM PDF

Microbiota
The role of microbiome in colorectal carcinogenesis and its clinical potential as a target for cancer treatment: Sang Hoon Kim, Yun Jeong Lim; Intest Res. 2022;20(1):31-42. Published online May 21, 2021; DOI: https://doi.org/10.5217/ir.2021.00034
Cited By 16; Full text PubReader ePub Crossref - TDM PDF

Inflammatory Bowel Diseases
Quality of life in inflammatory bowel diseases: it is not all about the bowel: Ronald Keller, Nazar Mazurak, Laura Fantasia, Stefano Fusco, Nisar P Malek, Jan Wehkamp, Paul Enck, Thomas Klag; Intest Res. 2021;19(1):45-52. Published online February 27, 2020; DOI: https://doi.org/10.5217/ir.2019.00135
Cited By 16; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study: Choon Jin Ooi, Ida Normiha Hilmi, Hyo-Jong Kim, Umesh Jalihal, Deng-Chyang Wu, Dirk Demuth, Dirk Lindner, Shashi Adsul; Intest Res. 2021;19(1):71-82. Published online September 4, 2020; DOI: https://doi.org/10.5217/ir.2019.09159
Cited By 16; Full text PubReader ePub Crossref - TDM PDF Supplementary Material

IBD
Pouchitis in inflammatory bowel disease: a review of diagnosis, prognosis, and treatment: Shintaro Akiyama, Victoria Rai, David T. Rubin; Intest Res. 2021;19(1):1-11. Published online November 5, 2020; DOI: https://doi.org/10.5217/ir.2020.00047
Cited By 16; Full text PubReader ePub Crossref - TDM PDF

Inflammatory Bowel Diseases
Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study: Yasuo Suzuki, Takashi Hagiwara, Mariko Kobayashi, Kazuo Morita, Tomoyo Shimamoto, Toshifumi Hibi; Intest Res. 2021;19(3):301-312. Published online August 20, 2020; DOI: https://doi.org/10.5217/ir.2020.00013
Cited By 15; Full text PubReader ePub Crossref - TDM PDF Supplementary Material Graphic abstract

Most cited